Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Clinical Cancer Research
Clinical Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Highlights

Selected Articles from This Issue

DOI:  Published May 2020
  • Article
  • Info & Metrics
  • PDF
Loading

Decitabine and Vorinostat for Relapsed ALL

Burke et al. Page 2297

Treatment failure from drug resistance is the primary reason for relapse in acute lymphoblastic leukemia (ALL). Burke and colleagues conducted a pilot clinical trial in patients with ALL using two classes of epigenetic modifying agents (decitabine and vorinostat) with the goal of synergistically targeting epigenetic alterations before and during chemotherap. that included UK ALLR3 re-induction. On this regimen, nine subjects (39%) achieved a complete response and five had stable disease (22%). Modulation of epigenetic marks was observed. However, the toxicity profile of the combination assessed was not acceptable. Therefore, future studies are necessary to determine if epigenetic modifying therapies can be successfully combined with chemotherapeutics for children with relapsed leukemia.

Immune Checkpoint Inhibitor with SBRT in PDAC

Xie et al. Page 2318

Metastatic pancreatic ductal adenocarcinoma (PDAC) carries a dismal prognosis and is refractory to conventional chemotherapy. Although immunotherapy has been safe and effective in multiple tumor types, the utility of immunotherapy is limited in PDAC. In a phase I study of patients with metastatic PDAC, Xie and colleagues investigated the tolerability and clinical efficacy of darmalumab with or without tremelimumab in combination with stereotactic body radiation therapy (SBRT). The combination of checkpoint inhibitors with SBRT was well tolerated and showed moderate efficacy, with an overall response rate of 5.1%. These findings reinforce the need for optimization of immunotherapeutic strategies in metastatic PDAC.

Plasma Tumor Mutation Burden and Response to Pembrolizumab

Aggarwal et al. Page 2354

Pembrolizumab-based therap. is currently the standard of care for patients with metastatic non-small cell lung cancer (mNSCLC) lacking actionable mutations. High tumor mutation burden (TMB) is associated with response to pembrolizumab, but current protocols for measuring TMB require obtaining sufficient tissue for analysis, which can be a challenge. Aggarwal and colleagues measured the plasma TMB (pTMB) of 66 patients with mNSCLC who received pembrolizumab monotherapy with or without chemotherapy. High baseline pTMB (greater than 16 mut/Mb) correlated with improved PFS after pembrolizumab-based therapy in mNSCLC. In addition, mutations in STK11, KEAP1, PTEN, and ERBB2 were identified in pTMB-high patients who did not respond. Although a larger validation study is needed, these results show the potential clinical utility of a plasma based TMB test to help inform therapy selection.

Preclinical HER2 Combination Therapy

Ivanova et al. Page 2393

The development of anti-cancer therapies requires appropriate preclinical models in which to test treatments. Roughly three percent of non-small cell lung cancers (NSCLC) harbor mutations in HER2, but there are limited models of HER2 mutant NSCLC available for preclinical study. Ivanova and colleagues assessed drug combinations in HER2-mutant (NSCLC) patient xenograft-derived organotypic spheroids (XDOTS) using a short-term ex vivo system. Two such models were generated, and successful drug combinations were identified for both. Therefore, the XDOTS platform can be used to evaluate therapies and therapeutic combinations ex vivo using PDX tumors, further enhancing precision medicine possibilities in NSCLC.

  • ©2020 American Association for Cancer Research.
PreviousNext
Back to top
Clinical Cancer Research: 26 (10)
May 2020
Volume 26, Issue 10
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Clinical Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Selected Articles from This Issue
(Your Name) has forwarded a page to you from Clinical Cancer Research
(Your Name) thought you would be interested in this article in Clinical Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Selected Articles from This Issue
Clin Cancer Res May 15 2020 (26) (10) 2279;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Selected Articles from This Issue
Clin Cancer Res May 15 2020 (26) (10) 2279;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Decitabine and Vorinostat for Relapsed ALL
    • Immune Checkpoint Inhibitor with SBRT in PDAC
    • Plasma Tumor Mutation Burden and Response to Pembrolizumab
    • Preclinical HER2 Combination Therapy
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Selected Articles from This Issue
  • Selected Articles from This Issue
  • Selected Articles from This Issue
Show more Highlights
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • CCR Focus Archive
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Clinical Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Clinical Cancer Research
eISSN: 1557-3265
ISSN: 1078-0432

Advertisement